

---

## CURRICULUM VITAE

### PERSONAL DATA:

**Name:** Mohammad Mansour S. Algahtani.  
**Nationality:** Saudi Arabia.  
**E-mail:** [mohgahtani@ksu.edu.sa](mailto:mohgahtani@ksu.edu.sa) / [Ph.m7md@hotmail.com](mailto:Ph.m7md@hotmail.com)  
**Mobile:** (966)-553492877.

### QUALIFICATIONS:

**2015-2019** Ph.D. Degree in Molecular Medicine and Pharmacogenomics, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, USA.  
**2007-2012** Bachelor's degree of Pharmaceutical Sciences, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

### PROFESSIONAL CLASSIFICATION:

**December 2022** Consultant.  
**December 2019** Senior Pharmacist.  
**January 2012** Pharmacist.

### CAREER HISTORY:

**2024- till now** Associate professor, Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.  
**2019- 2024** Assistant professor, Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.  
**2016-2019** Research Assistant, Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, USA.  
**2015-2016** Teaching Assistant, Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, USA.  
**2013-2019** Teaching Assistant, Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.  
**2012-2013** Pharmacist II at National Guard Hospital "King Abdulaziz Medical City, Riyadh, Saudi Arabia.

### ADMINISTRATIVE POSITIONS:

**2022- till now** Vice President of the Business Unit, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.  
**2021-2022** Supervisor of the Faculty Support Division, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.  
**2020-2021** Assistant Supervisor of the Postgraduate Studies Unit, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

**PROFESSIONAL TRAINING:**

- June 2010** Internship for six weeks at **Health House Pharmacy**, Riyadh, Saudi Arabia.
- July 2010** Internship for five weeks in quality and research department at **Pfizer Company**, Riyadh, Saudi Arabia.
- July 2011** Internship for five weeks in outpatient and inpatient pharmacies at **Kingdom Hospital**, Riyadh, Saudi Arabia.

**WORKSHOP AND CONFERENCE:**

- April 2011** Total Parenteral Nutrition Workshop at King Saud University, Riyadh, Saudi Arabia.
- April 2012** The 2<sup>nd</sup> international Cardiovascular Pharmacotherapy Conference & Exhibition, Riyadh, Saudi Arabia.
- April 2017** Poster presentation, American Association for Cancer Research (AACR), Washington D.C, USA.
- October 2017** Poster presentation, Cancer Research and Targeted Therapy (CRT), Miami FL, USA.
- April 2019** Poster presentation, American Association for Cancer Research (AACR), Atlanta GA, USA.
- April 2020** Poster presentation, American Association for Cancer Research (AACR), Philadelphia PA, USA.
- January 2021** Participate as a speaker at Scientific Research Week, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
- March 2021** Participate as an organizer at College of Pharmacy Research Day (COPRD10), King Saud University, Riyadh, Saudi Arabia.
- February 2022** Participate as a speaker at Basic Research Skills workshop, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
- May 2022** Poster presentation, College of Pharmacy Research Day (COPRD11), King Saud University, Riyadh, Saudi Arabia.
- May 2023** Poster presentation, College of Pharmacy Research Day (COPRD12), King Saud University, Riyadh, Saudi Arabia.
- January 2024** Participate as an expert in SIPHA's Networking Hub, 7<sup>th</sup> SIPHA: Saudi International Pharmaceutical Science Meeting & Workshops, Riyadh, Saudi Arabia.
- April 2024** Poster presentation, American Association for Cancer Research (AACR), San Diego CA, USA.
- May 2024** Participate as a poster judge, College of Pharmacy Research Day (COPRD13), King Saud University, Riyadh, Saudi Arabia.

**RESEARCH PAPERS:**

1. Khalid Alhazzani, Ali Alaseem, **Mohammad Algahtani**, Sivanesan Dhandayuthapani, Thiagarajan Venkatesan, and Appu, Rathinavelu; **Angiogenesis in Cancer Treatment: 60 Years' Swing Between Promising Trials and Disappointing Tribulations**. *Anti-Angiogenesis Drug Discovery and Development* (2019). <https://doi.org/10.2174/9781681083971119040005>.
2. Thanigaivelan Kanagasabai, Thiagarajan Venkatesan, Umamaheswari Natarajan, Saad Alobid, Khalid Alhazzani, **Mohammad Algahtani**, and Appu Rathinavelu; **Regulation of cell cycle by MDM2 in prostate cancer cells through Aurora Kinase-B and p21WAF1/CIP1 mediated pathways**. *Cellular Signalling* (2020). <https://doi.org/10.1016/j.cellsig.2019.109435>.
3. Naif O Al-harbi, Faisal Imam, Mohammad Matar Alharbi, Mohammad Rashid Khan, Wajhul Qamar, Muhammad Afzal, **Mohammad Algahtani**, Saad Alobaid, Ali Salim Alfardan, Abdulrahman Alshammari, Thamer H Albekairi, and Khalid Saad Alharbi; **Role of rivaroxaban in sunitinib-induced renal injuries via inhibition of oxidative stress-induced apoptosis and inflammation through the tissue necrosis factor- $\alpha$  induced nuclear factor-kappa B signaling pathway in rats**. *Journal of Thrombosis and Thrombolysis* (2020). <https://doi.org/10.1007/s11239-020-02123-6>.
4. Abdulaziz Alaqil, Meshary Alkahtani, and **Mohammad Algahtani**; **Prevalence and Predictors of Glycemic Control in Hospitalized Patients with Diabetes**. *Indian Journal of Public Health Research & Development* (2020). <https://doi.org/10.37506/ijphrd.v11i11.11411>.
5. Ashraf M. Mahmoud, Mater H. Mahnashi, Khalid Alhazzani, Alanazi AZ, **Mohammad M. Algahtani**, Ali Alaseem, Bandar A. Alyami, Ali O. AlQarni, and Mohamed M. El-Wekil; **Nitrogen doped graphene quantum dots based on host guest interaction for selective dual readout of dopamine**. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* (2021). <https://doi.org/10.1016/j.saa.2021.119516>.
6. Mater H. Mahnashi, Ashraf M. Mahmoud, Khalid Alhazzani, A. Z. Alanazi, Ali Mohammed Alaseem, **Mohammad M. Algahtani**, and Mohamed M. El-Wekil; **Ultrasensitive and selective molecularly imprinted electrochemical oxaliplatin sensor based on a novel nitrogen-doped carbon nanotubes/Ag@cu MOF as a signal enhancer and reporter nanohybrid**. *Microchim Acta* (2021). <https://doi.org/10.1007/s00604-021-04781-6>.
7. Mater H. Mahnashi, Ashraf M. Mahmoud, Khalid Alhazzani, Alanazi AZ, **Mohammad M. Algahtani**, Ali Mohammed Alaseem, Yahya S.A. Alqahtani, and Mohamed M. El-Wekil; **Enhanced molecular imprinted electrochemical sensing of histamine based on signal reporting nanohybrid**. *Microchemical Journal* (2021). <https://doi.org/10.1016/j.microc.2021.106439>.
8. Khalid Alhazzani, Sheikh F. Ahmad, Naif O. Al-Harbi, Sabry M. Attia, Saleh A. Bakheet, Wedad Sarawi, Saleh A. Alqarni, **Mohammad Algahtani**, and Ahmed Nadeem; **Pharmacological Inhibition of STAT3 by Stattic Ameliorates Clinical Symptoms and Reduces Autoinflammation in Myeloid, Lymphoid, and Neuronal Tissue Compartments in Relapsing-Remitting Model of Experimental Autoimmune Encephalomyelitis in SJL/J Mice**. *Pharmaceutics* (2021). <https://doi.org/10.3390/pharmaceutics13070925>.
9. Haneen A. Al-Mazroua, Ahmed Nadeem, Mushtaq A. Ansari, Sabry M. Attia, Saleh A. Bakheet, Thamer H. Albekairi, Nemat Ali, Fawaz Alasmari, **Mohammad Algahtani**, Abdulaziz M.S. Alsaad, and Sheikh F. Ahmad; **CCR1 antagonist ameliorates experimental autoimmune encephalomyelitis by inhibition of Th9/Th22-related markers in the brain and periphery**. *Molecular Immunology* (2022). <https://doi.org/10.1016/j.molimm.2022.02.017>.
10. **Mohammad Algahtani**, Umamaheswari Natarajan, Khalid Alhazzani, Ali Alaseem, and Appu Rathinavelu; **Evaluation of Anti-angiogenic Agent F16 for Targeting Glioblastoma Xenograft Tumors**. *Cancer Genetics* (2022). <https://doi.org/10.1016/j.cancergen.2022.04.001>.
11. Ahmed Nadeem, Sheikh F. Ahmad, Naif O. Al-Harbi, Laila Y Al-Ayadhi, Mohammed M Alanazi, Ali S Alfardan, Sabry M Attia, **Mohammad Algahtani**, and Saleh A Bakheet; **Dysregulated Nrf2 signaling in response to di(2-ethylhexyl) phthalate in neutrophils of children with autism**. *International Immunopharmacology* (2022). <https://doi.org/10.1016/j.intimp.2022.108619>.
12. Khalid Alhazzani, Thiagarajan Venkatesan, Umamaheswari Natarajan, **Mohammad Algahtani**, Ali Alaseem, Saad Alobid, and Appu Rathinavelu; **Evaluation of antitumor effects of VEGFR-2**

- inhibitor F16 in a colorectal xenograft model. *Biotechnology Letters* (2022). <https://doi.org/10.1007/s10529-022-03243-0>.
13. Yousif S. Alakeel, Meshary M. Alkahtani, Omar M. Hijazi, and **Mohammad M. Algahtani**; **Vasopressin associated hyponatremia in critically ill children: A cross-sectional study.** *Saudi Pharmaceutical Journal* (2022). <https://doi.org/10.1016/j.jsps.2022.06.006>.
  14. Mashal M. Almutairi, Ahmed Nadeem, Mushtaq A. Ansari, Saleh A. Bakheet, Sabry M. Attia, Thamer H. Albekairi, Khaled Alhosaini, **Mohammad Algahtani**, Abdulaziz M.S. Alsaad, Haneen A. Al-Mazroua, and Sheikh F. Ahmad; **Lead (Pb) exposure exacerbates behavioral and immune abnormalities by upregulating Th17 and NF- $\kappa$ B-related signaling in BTBR T+ Itpr3tf/J autistic mouse model.** *NeuroToxicology* (2022). <https://doi.org/10.1016/j.neuro.2022.06.007>.
  15. Abdullah S. Alhamed, Mohammed Alqinyah, Musab A. Alsufayan, Ibrahim A. Alhaydan, Yasseen A. Alasmrri, Hajar O. Alnefaie, **Mohammad M. Algahtani**, Adel F. Alghaith, Hussain N. Alhamami, Abdullah M. Albogami, Khalid Alhazzani, and Alanazi AZ; **Blockade of store-operated calcium entry sensitizes breast cancer cells to cisplatin therapy via modulating inflammatory response.** *Saudi Pharmaceutical Journal* (2023). <https://doi.org/10.1016/j.jsps.2022.12.009>.
  16. Ali M. Alaseem, Khalid Alhazzani, Ahmed Zuwaiel Alanazi, Yasser Alqarni, **Mohammad M. Algahtani**, Abdullah S. Alhamed, Glowi Alasiri, Fahad T. Alotaibi, Talha Jawaid, and Jehad A. Aldali; **Preclinical In Vitro Investigation of MDM2 Inhibition in Combination with Antiangiogenic Therapy for Breast Cancer Treatment.** *Scientia Pharmaceutica* (2023). <https://doi.org/10.3390/scipharm91010012>.
  17. Sana Hanif, Muhammad Ali Syed, Ahmad Junaid Rashid, Tareq Nafea Alharby, **Mohammad M. Algahtani**, Muteb Alanazi, Jowaher Alanazi, and Rai Muhammad Sarfraz; **Validation of a Novel RP-HPLC Technique for Simultaneous Estimation of Lignocaine Hydrochloride and Tibezonium Iodide: Greenness Estimation Using AGREE Penalties.** *Molecules* (2023). <https://doi.org/10.3390/molecules28083418>.
  18. **Mohammad M. Algahtani**, Samiyah Alshehri, Sana S. Alqarni, Sheikh F. Ahmad, Naif O. Al-Harbi, Saleh A. Alqarni, Ali S. Alfardan, Khalid E. Ibrahim, Sabry M. Attia, and Ahmed Nadeem; **Inhibition of ITK Signaling Causes Amelioration in Sepsis-Associated Neuroinflammation and Depression-like State in Mice.** *International Journal of Molecular Sciences* (2023). <https://doi.org/10.3390/ijms24098101>.
  19. Talib Hussain, Muteb Alanazi, Jowaher Alanazi, Tareq Nafea Alharby, Aziz Unnisa, Amir Mahgoub Awadelkareem, AbdElmoneim O. Elkhalfifa, **Mohammad M. Algahtani**, SMA Shahid, and Syed Mohd Danish Rizvi; **Computational and In Vitro Assessment of a Natural Triterpenoid Compound Gedunin against Breast Cancer via Caspase 3 and Janus Kinase/STAT Modulation.** *Processes* (2023). <https://doi.org/10.3390/pr11051452>.
  20. Mohammed Alqinyah, Abdullah S. Alhamed, Hajar O. Alnefaie, **Mohammad M. Algahtani**, Amira M. Badr, Abdullah M. Albogami, Mohamed Mohany, Yasseen A. Alasmrri, Adel F. Alghaith, Hussain N. Alhamami, Khalid Alhazzani, Ahmed Z. Alanazi, and Omar Awad Alsaïdan; **Targeting Store-Operated Calcium Entry Regulates the Inflammation-Induced Proliferation and Migration of Breast Cancer Cells.** *Biomedicines* (2023). <https://doi.org/10.3390/biomedicines11061637>.
  21. **Mohammad M. Algahtani**, Sheikh F. Ahmad, Layla A. Alkharashi, Naif O. Al-Harbi, Wael A. Alanazi, Abdullah S. Alhamed, Sabry M. Attia, Saleh A. Bakheet, Khalid E. Ibrahim, and Ahmed Nadeem; **Exposure to Methylmercury at Juvenile Stage Worsens Autism-like Symptoms in Adult BTBR T+tf/J Mice Due to Lack of Nuclear Factor Erythroid 2-Related Factor 2 Signaling Upregulation in Periphery and Brain.** *Toxics* (2023). <https://doi.org/10.3390/toxics11060546>.
  22. Ahmed Z. Alanazi, Khalid Alhazzani, Salah Q. Alrewily, Khaldoon Algerian, **Mohammad M. Algahtani**, Qamraa H. Alqahtani, Dhanush Haspula, Abdullah S. Alhamed, Mohammed Alqinyah, and Mohammad Raish; **The Potential Protective Role of Naringenin against Dasatinib-Induced Hepatotoxicity.** *Pharmaceuticals* (2023). <https://doi.org/10.3390/ph16070921>.
  23. Khalid Alhazzani, Salah Q. Alrewily, Khaldoon Algerian, Khaled Alhosaini, **Mohammad M. Algahtani**, Mohammed Fhad Almutery, Abdullah S. Alhamed, Ahmed Nadeem, Moureq R.

- Alotaibi, and Ahmed Z. Alanazi; **Hydroxychloroquine ameliorates dasatinib-induced liver injury via decrease in hepatic lymphocytes infiltration.** *Human and Experimental Toxicology* (2023). <http://dx.doi.org/10.1177/09603271231188492>.
24. Abdullah S. Alhamed, Mohammed Alqinyah, Adel F. Alghaith, **Mohammad M. Algahtani**, Faleh Alqahtani, Fahd A. Nasr, Ali S. Alqahtani, Omar M. Noman, Abdulrahman S. Bazaid, Reem Hussain AlMalki, Anas M. Abdel Rahman, Khalid Alhazzani, and Ahmed Z. Alanazi; **Phytochemical analysis and anticancer activity of the *Pithecellobium dulce* seed extract in colorectal cancer cells.** *Open Chemistry* (2023). <https://doi.org/10.1515/chem-2023-0362>.
25. Tareq Nafea Alharby, **Mohammad M. Algahtani**, Jowaher Alanazi, and Muteb Alanazi; **Advancing nanomedicine production via green thermal supercritical processing: Laboratory measurement and thermodynamic modeling.** *Journal of Molecular Liquids* (2023). <https://doi.org/10.1016/j.molliq.2023.122042>.
26. Jowaher Alanazi, **Mohammad M. Algahtani**, Muteb Alanazi, and Tareq Nafea Alharby; **Application of different mathematical models based on artificial intelligence technique to predict the concentration distribution of solute through a polymeric membrane.** *Ecotoxicology and Environmental Safety* (2023). <https://doi.org/10.1016/j.ecoenv.2023.115183>.
27. Khalid Alhazzani, Meshal Alsahli, Ahmed Z Alanazi, **Mohammad Algahtani**, Ahmad A Alenezi, Ali Alhoshani, Mohammed Alqinyah, Abdullah S. Alhamed, and Khaled Alhosaini; **Augmented antitumor effects of erlotinib and cabozantinib on A549 nonsmall cell lung cancer: In vitro and in vivo studies.** *Saudi Pharmaceutical Journal* (2023). <https://doi.org/10.1016/j.jsps.2023.101756>.
28. Layla A. Al-Kharashi, Naif O. Al-Harbi, Sheikh F. Ahmad, Sabry M. Attia, **Mohammad M. Algahtani**, Khalid E. Ibrahim, Saleh A. Bakheet, Mohammed M. Alanazi, Saleh A. Alqarni, Sary Alsanea, and Ahmed Nadeem; **Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE.** *Biomedicines* (2023). <https://doi.org/10.3390/biomedicines11092502>.
29. Layla A. Al-Kharashi, Saleh A. Alqarni, Sheikh F. Ahmad, Naif O. AlHarbi, Sary Alsanea, Khalid E. Ibrahim, **Mohammad M. Algahtani**, Khalid Alhazzani, Gamal A. Shazly, Mohammad M. Al-Harbi, and Ahmed Nadeem; **BALB/c and C57BL/6 mice differ in oxidant and antioxidant responses in innate and adaptive immune cells in an asthma model induced by cockroach allergens.** *International Immunopharmacology* (2023). <https://doi.org/10.1016/j.intimp.2023.110892>.
30. Hussain N. Alhamami, Abdullah M. Albogami, **Mohammad M. Algahtani**, Mohammed Alqinyah, Wael A. Alanazi, Fawaz Alasmari, Khalid Alhazzani, Ahmed Z. Alanazi, Yasseen A. Alasmrri, and Abdullah S. Alhamed; **The effect of inhibiting hindbrain A2 noradrenergic neurons by 6-Hydroxydopamine on lipopolysaccharide-treated male rats autistic animal model.** *Saudi Pharmaceutical Journal* (2024). <https://doi.org/10.1016/j.jsps.2024.101964>.
31. **Mohammad M. Algahtani**, Sheikh F. Ahmad, Naif O. Al-Harbi, Laila Y Al-Ayadhi, Khalid Alhazzani, Sabry M Attia, Ahmed Z. Alanazi, Saleh A Bakheet, and Ahmed Nadeem; **Dysregulated Antioxidant Network and Increased iNOS Signaling in Platelets of Children with Autism Spectrum Disorder.** *Journal of Biological Regulators and Homeostatic Agents* (2024). <https://doi.org/10.23812/j.biol.regul.homeost.agents.20243805.340>.
32. Khalid Alhazzani, Hanan Mohammed, **Mohammad M Algahtani**, Khaldoon Algerian, Ali Alhoshani, Homood M As Sobeai, Syed Rizwan Ahamad, Moureq R Alotaibi, Abdullah S Alhamed, Fawaz Alasmari, Mohammed Alqinyah, Hussain N Alhamami, and Ahmed Z Alanazi; **Integrating Metabolomics, Histopathology, and Cardiac Marker Analysis to Assess Valsartan’s Efficacy in Mitigating Dasatinib-Induced Cardiac Toxicity in Sprague-Dawley Rats.** *Drug Design, Development and Therapy* (2024). <https://doi.org/10.2147/DDDT.S497212>.

#### **PUBLISHED ABSTRACT:**

1. **Mohammad Algahtani**, Khalid Alhazzani, Thiagarajan Venkatesan, Appu Rathinavelu, (2017) **Apoptosis pathway focused gene expression profiling of a novel VEGFR2 inhibitor**, Presented at American Association for Cancer Research (AACR) April 1-4, Washington D.C, USA.

2. **Mohammad Algahtani**, Khalid Alhazzani, Sivanesan Dhandayuthapani, Thanigaivelan Kanagasabai, Appu Rathinavelu, (2017) **F16 is a novel new candidate for brain tumors**, Presented at Cancer Research and Targeted Therapy (CRT) Oct 26-28, Miami FL, USA.
3. **Mohammad Algahtani**, Khalid Alhazzani, Thiagarajan Venkatesan, Ali Alaseem, Sivanesan Dhandayuthapani and Appu Rathinavelu, (2019) **Direct cytotoxic effect of a novel anti-angiogenic drug F16 towards U87MG glioblastoma cell line**, Presented at American Association for Cancer Research (AACR) March 29<sup>th</sup> – April 3<sup>rd</sup>, Atlanta GA, USA.
4. Appu Rathinavelu, **Mohammad Algahtani**, Umamaheswari Natarajan, Jayanta Das, Thiagarajan Venkatesan, (2020) **A novel anti-angiogenic agent F16 for the treatment of glioblastoma**, Presented at American Association for Cancer Research (AACR) April 27<sup>th</sup> – 28<sup>th</sup> and June 22<sup>nd</sup> – 24<sup>th</sup>, Philadelphia PA, USA.
5. Juan Anderson, Mariah Delgado, Malcolm Lovett, Maya Saunders, Geovannie Lake, Samuel Darko, Rose M. Stiffin, Ayivi Huisso, Marilyn Sherman, Latoya Appleton, Amalya Mihnea, Swarnava Das, **Mohammad M. Algahtani**, Ravi Vadapalli, Biswarup Basu, Arunima Biswas, Noor Neha, Madhumita Das, Marco A. Ruiz, Mayur Doke, Jayanta K. Das, (2024) **Development of non-smoking lung cancers by indoor carcinogenic aerosols through epigenetic reprogramming of lung stem cells: Bioinformatics and artificial intelligence analysis**, Presented at American Association for Cancer Research (AACR) April 5<sup>th</sup> – 10<sup>th</sup>, San Diego CA, USA.

#### **PATENT:**

1. Appu Rathinavelu, Thiagarajan Venkatesan, Jayanta Das, and **Mohammad Mansour S. Algahtani**; Methods and composition for treatment of solid tumors using F16 isoindole small molecules (2022). Patent Publication Number: US20220409581.

#### **HONORS AND AWARDS:**

- Excellence Reward from King Saud University – 2010.
- Excellence Reward from King Saud University – 2011.
- Excellence Reward from King Saud University – 2012.
- 2<sup>nd</sup> Best-poster award, College of Pharmacy Research Day (COPRD2), King Saud University – 2012.
- Excellence Reward from Saudi Arabian Culture Mission – 2015.
- Excellence Reward from Saudi Arabian Culture Mission – 2016.